Compounds > diphenylprolinol
Page last updated: 2024-12-08

diphenylprolinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diphenylprolinol: a psychoactive drug; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID204386
CHEMBL ID1625964
SCHEMBL ID100361
MeSH IDM0578572

Synonyms (63)

Synonym
LS-14575
(r)-alpha-(2-pyrrolidinyl)benzhydryl alcohol
diphenyl(2-pyrrolidinyl)methanol
s-(-)-1,1-diphenylprolinol
IDI1_014511
OPREA1_549580
SR-01000473497-2
MAYBRIDGE3_003124 ,
HMS1439N22
diphenyl(pyrrolidin-2-yl)methanol
STK894096
di(phenyl)-pyrrolidin-2-ylmethanol
inchi=1/c17h19no/c19-17(16-12-7-13-18-16,14-8-3-1-4-9-14)15-10-5-2-6-11-15/h1-6,8-11,16,18-19h,7,12-13h2
ogcgxugbdjgffy-uhfffaoysa-
(r)-(+)-2-(diphenylhydroxymethyl)pyrrolidine
AKOS001637329
NCGC00245754-01
(s)-(-)-diphenylpyrrolidinemethanol
(r)-(+)-diphenylpyrrolidinemethanol
diphenyl(2-pyrrolidinyl)methanol;(s)-(-)-alpha,alpha-diphenyl-2-pyrrolidinemethanol
2-pyrrolidininemethanol, alpha,alpha-diphenyl-, (r)-
unii-d56js74ww2
(+)-alpha,alpha-diphenyl-2-pyrrolidininemethanol
diphenylprolinol
d56js74ww2 ,
CCG-46705
FT-0605103
BBL021383
AB00086196-01
AKOS022061527
SCHEMBL100361
SY006464
mfcd00075506
mfcd00077754
SY007355
d2pm
CHEMBL1625964
AE-848/01538048
SR-01000473497-1
sr-01000473497
mfcd00425883
63401-04-7
diphenyl-2-pyrrolidinyl-methanol
alpha,alpha-diphenyl-2-pyrrolidinemethanol
Q5279745
BCP27179
(+/-)-.alpha.,.alpha.-diphenyl-2-pyrrolidinemethanol
(+/-)-alpha,alpha-diphenyl-2-pyrrolidinemethanol
(+/-)-2-(diphenylhydroxymethyl)pyrrolidine
54U9UN7HN4 ,
.alpha.,.alpha.-diphenylpyrrolidin-2-ylmethanol
unii-54u9un7hn4
.alpha.,.alpha.-diphenyl-2-pyrrolidinemethanol
1,1-diphenylprolinol
alpha,alpha-diphenylpyrrolidin-2-ylmethanol
2-pyrrolidinemethanol, alpha,alpha-diphenyl-
2-pyrrolidinemethanol, .alpha.,.alpha.-diphenyl-
(r)-(+)- alpha,alpha-diphenylprolinol
tert-butyl2-morpholin-2-ylethylcarbamate
A900216
(s)-(-)-?,?-diphenyl-2-pyrrolidinemethanol
DTXSID001336517
,-diphenyl-2-pyrrolidinemethanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (72.73)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.74 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index35.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ether
Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.		7.4110ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
4-butyrolactone
4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.		2.3110butan-4-olidemetabolite;
neurotoxin
3-hydroxybutanal
[no description available]		2.3110
propadiene
[no description available]		2.0810allenes
butenolide
butenolide: inhibits experimental allergic encephalomyelitis in rats. butenolide : A gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives.		2.3110butenolide
2-diphenylmethylpiperidine
2-diphenylmethylpiperidine: structure given in first source; RN given refers to compound with no isomeric designation		4.0920
piperidines
Piperidines: A family of hexahydropyridines.		4.0920
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310